Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Free Cash Flow (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Free Cash Flow data on record, last reported at $19.6 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 176.35% year-over-year to $19.6 million; the TTM value through Dec 2025 reached -$25.0 million, up 38.4%, while the annual FY2025 figure was -$25.0 million, 38.4% up from the prior year.
  • Free Cash Flow reached $19.6 million in Q4 2025 per TGTX's latest filing, up from -$23.2 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $83.7 million in Q3 2023 and bottomed at -$87.0 million in Q4 2021.
  • Average Free Cash Flow over 5 years is -$28.5 million, with a median of -$27.2 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: soared 342.63% in 2023, then plummeted 250.19% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$87.0 million in 2021, then skyrocketed by 72.56% to -$23.9 million in 2022, then soared by 44.67% to -$13.2 million in 2023, then crashed by 94.26% to -$25.7 million in 2024, then surged by 176.35% to $19.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $19.6 million in Q4 2025, -$23.2 million in Q3 2025, and $7.4 million in Q2 2025.